Aligos Therapeutics, Inc. Increase (Decrease) in Accrued Liabilities
Aligos Therapeutics, Inc. (ALGS) reported Increase (Decrease) in Accrued Liabilities of $5.17 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-06
- Aligos Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $6.71M, a 374.66% increase year-over-year.
- Aligos Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$1.54M.
- Aligos Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was -$79.00K, a 106.11% decline year-over-year.
- Aligos Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $1.40M, a 33.24% decline year-over-year.
- Aligos Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was -$2.03M.
- Aligos Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was -$1.39M, a 251.20% decline from fiscal 2023.
- Aligos Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2023 was $918.00K.
- Aligos Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2022 was -$9.14M, a 193.82% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $5.17M 10-Q · filed 2026-08-06 | $5.09M derived: sum of 3 quarters · filed 2026-08-06 | $6.49M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$1.54M 10-Q · filed 2026-05-07 | -$1.62M derived: sum of 2 quarters · filed 2026-05-07 | -$216.00K derived: sum of 3 quarters · filed 2026-05-07 | $1.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$79.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.32M derived: sum of 2 quarters · filed 2026-03-05 | $2.73M derived: sum of 3 quarters · filed 2026-08-06 | -$2.03M 10-K · filed 2026-03-05 |
| 2025-09-30 | $1.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.81M derived: sum of 2 quarters · filed 2026-08-06 | -$1.95M 10-Q · filed 2025-11-06 | -$659.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$3.35M 10-Q · filed 2026-08-06 | -$2.06M derived: sum of 3 quarters · filed 2026-08-06 | $38.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$4.76M 10-Q · filed 2026-05-07 | -$3.47M derived: sum of 2 quarters · filed 2026-05-07 | -$1.38M derived: sum of 3 quarters · filed 2026-05-07 | -$1.35M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $3.39M derived: sum of 2 quarters · filed 2026-03-05 | $3.41M derived: sum of 3 quarters · filed 2026-03-05 | -$1.39M 10-K · filed 2026-03-05 |
| 2024-09-30 | $2.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.12M derived: sum of 2 quarters · filed 2025-11-06 | -$2.68M 10-Q · filed 2025-11-06 | $1.89M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $22.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$4.78M 10-Q · filed 2025-08-06 | -$203.00K derived: sum of 3 quarters · filed 2025-08-06 | -$1.66M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$4.80M 10-Q · filed 2025-05-06 | -$225.00K derived: sum of 2 quarters · filed 2025-05-06 | -$1.68M derived: sum of 3 quarters · filed 2025-05-06 | -$2.94M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $4.58M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $3.12M derived: sum of 2 quarters · filed 2025-03-10 | $1.85M derived: sum of 3 quarters · filed 2025-03-10 | $918.00K 10-K · filed 2025-03-10 |
| 2023-09-30 | -$1.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$2.72M derived: sum of 2 quarters · filed 2024-11-06 | -$3.66M 10-Q · filed 2024-11-06 | -$1.27M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$1.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$2.20M 10-Q · filed 2024-08-06 | $186.00K derived: sum of 3 quarters · filed 2024-08-06 | $1.08M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$937.00K 10-Q · filed 2024-05-07 | $1.45M derived: sum of 2 quarters · filed 2024-05-07 | $2.35M derived: sum of 3 quarters · filed 2024-05-07 | -$4.01M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $2.39M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $3.29M derived: sum of 2 quarters · filed 2024-03-12 | -$3.07M derived: sum of 3 quarters · filed 2024-03-12 | -$9.14M 10-K · filed 2024-03-12 |
| 2022-09-30 | $897.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$5.46M derived: sum of 2 quarters · filed 2023-11-02 | -$11.53M 10-Q · filed 2023-11-02 | -$7.65M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | -$6.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$12.43M 10-Q · filed 2023-08-03 | -$8.54M derived: sum of 3 quarters · filed 2023-08-03 | -$4.54M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$6.07M 10-Q · filed 2023-05-04 | -$2.19M derived: sum of 2 quarters · filed 2023-05-04 | $1.81M derived: sum of 3 quarters · filed 2023-05-04 | $7.91M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $3.88M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $7.88M derived: sum of 2 quarters · filed 2023-03-09 | $13.98M derived: sum of 3 quarters · filed 2023-03-09 | $9.74M 10-K · filed 2023-03-09 |
| 2021-09-30 | $4.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $10.10M derived: sum of 2 quarters · filed 2022-11-02 | $5.86M 10-Q · filed 2022-11-02 | $13.55M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-30 | $6.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $1.86M 10-Q · filed 2022-08-04 | $9.55M derived: sum of 3 quarters · filed 2022-08-04 | $9.37M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | -$4.24M 10-Q · filed 2022-05-04 | $3.45M derived: sum of 2 quarters · filed 2022-05-04 | $3.27M derived: sum of 3 quarters · filed 2022-05-04 | $5.14M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | $7.69M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $7.50M derived: sum of 2 quarters · filed 2022-03-10 | $9.38M derived: sum of 3 quarters · filed 2022-03-10 | $9.57M 10-K · filed 2022-03-10 |
| 2020-09-30 | -$186.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $1.69M derived: sum of 2 quarters · filed 2021-11-04 | $1.88M 10-Q · filed 2021-11-04 | $4.46M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $1.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $2.06M 10-Q · filed 2021-08-05 | $4.64M derived: sum of 3 quarters · filed 2021-08-05 | |
| 2020-03-31 | $183.00K 10-Q · filed 2021-05-10 | $2.77M derived: sum of 2 quarters · filed 2021-05-10 | ||
| 2019-12-31 | $2.58M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | $4.22M 10-K · filed 2021-03-23 | ||
| 2019-09-30 | $1.64M 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |